Medical Oncology

Uzm. Dr. Barış Gezici

Doctor and researcher İzmir Şehir Hastanesi İzmir
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • Institutionİzmir Şehir Hastanesisaglik.gov.trFrom source
  • Publications10 publicationsOpenAlex, Europe PMCFrom source
  • ORCID0000-0003-1151-6523ORCIDFrom source
  • Last synchronised5 November 2026 09:07https://izmirsehir.saglik.gov.tr/TR-1046789/doktorlarimiz.html#baris-gezicisaglik.gov.tr

Scientific work

Publications

10 publications

  1. Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab

    Immunotherapy, 2026

    DOI 10.1080/1750743x.2026.2662201 PMID 42011533 4 citations (Europe PMC) Open-access full textSource: OpenAlex

  2. Successful rapid desensitization with 5-fluorouracil in a patient with metastatic sigmoid colon cancer: A case report

    Journal of Oncology Pharmacy Practice, 2026

    DOI 10.1177/10781552261478571 PMID 42585552 Source: OpenAlex

  3. Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group

    International Journal of Cancer, 2025

    DOI 10.1002/ijc.70213 PMID 41147655 3 citations (Europe PMC) Source: OpenAlex

  4. Prevalence of Insomnia and Associated Factors in Female Patients Undergoing Chemotherapy

    Nature and science of sleep, 2025

    DOI 10.2147/nss.s554960 PMID 41084526 1 citation (Europe PMC) Open-access full textSource: Europe PMC

  5. CT-230 Evaluation of BK Polyomavirus Infection Frequency and Risk Factors Following Allogeneic Stem Cell Transplantation (allo-SCT): A Single Center Experience

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)01500-8 Source: OpenAlex

  6. POSTER: CT-232 Evaluation of the Effects of Cytomegalovirus and BK Polyomavirus Infections on Overall Survival Following Allogeneic Stem Cell Transplantation: A Single Center Experience

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)00889-3 Source: OpenAlex

  7. CT-232 Evaluation of the Effects of Cytomegalovirus and BK Polyomavirus Infections on Overall Survival Following Allogeneic Stem Cell Transplantation: A Single Center Experience

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)01501-x Source: OpenAlex

  8. POSTER: CT-127 Evaluation of Cytomegalovirus Infection/Disease Frequency and Risk Factors Following Allogeneic Stem Cell Transplantation: A Single Center Experience

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)00914-x Source: OpenAlex

  9. CT-127 Evaluation of Cytomegalovirus Infection/Disease Frequency and Risk Factors Following Allogeneic Stem Cell Transplantation: A Single Center Experience

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)01488-x Open-access full textSource: OpenAlex

  10. POSTER: CT-230 Evaluation of BK Polyomavirus Infection Frequency and Risk Factors Following Allogeneic Stem Cell Transplantation (allo-SCT): A Single Center Experience

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)00888-1 Source: OpenAlex